Evidence map›Paper›PMID 41172233›Full record

ArticleBlood advances2026

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Shanshan Suo, Rongfeng Fu, Albert Qin, Zonghong Shao, Jie Bai, Hu Zhou, Na Xu, Suning Chen, Xuelan Zuo, Xin Du and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Shanshan SuoDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Rongfeng FuState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Albert QinPharmaEssentia Corporation, Taipei, Taiwan, Republic of China.ORCID 0000-0001-7610-084X
Zonghong ShaoDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Jie BaiDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Hu ZhouDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
Na XuDepartment of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, China.
Suning ChenDepartment of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0000-0001-6294-972X
Xuelan ZuoDepartment of Hematology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Xin DuDepartment of Hematology, Shenzhen Second People's Hospital, Shenzhen, China.
Minghui DuanDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0003-2130-6300
Li WangDepartment of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Pei LiDepartment of Hematology, Huashan Hospital of Fudan University, Shanghai, China.
Xuhan ZhangDepartment of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Sujiang ZhangDepartment of Hematology, Ruijin Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, China.ORCID 0000-0002-8481-0697
Daoxiang WuPharmaEssentia Biotech (Beijing) Limited, Beijing, China.
Jingjing ZhangPharmaEssentia Biotech (Beijing) Limited, Beijing, China.
Zhijian XiaoState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Lei ZhangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41172233
PMCPMC12856312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.